TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$8.46

Market cap

$9.33B

P/E Ratio

12.82

Dividend/share

N/A

EPS

$0.66

Enterprise value

$31.46B

Highlights
TEVA's net income has surged by 119% since the previous quarter and by 118% year-on-year
Teva Pharmaceutical Industries's EPS has surged by 118% QoQ and by 118% YoY
TEVA's quick ratio is down by 5% from the previous quarter
TEVA's revenue is down by 2.6% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: PFE MRK

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.1B
Market cap
$9.33B
Enterprise value
$31.46B
Valuations
Price to earnings (P/E)
12.82
Price to book (P/B)
0.89
Price to sales (P/S)
0.57
EV/EBIT
15.61
EV/EBITDA
9.2
EV/Sales
1.94
Earnings
Revenue
$16.23B
EBIT
$2.02B
EBITDA
$3.42B
Free cash flow
$34M
Per share
EPS
$0.66
Free cash flow per share
$0.03
Book value per share
$9.49
Revenue per share
$14.72
TBVPS
$17.99
Balance sheet
Total assets
$47.85B
Total liabilities
$36.4B
Debt
$24.17B
Equity
$10.47B
Working capital
$329M
Liquidity
Debt to equity
2.31
Current ratio
1.03
Quick ratio
0.52
Net debt/EBITDA
6.47
Margins
EBITDA margin
21.1%
Gross margin
46.8%
Net margin
4.5%
Operating margin
12.1%
Efficiency
Return on assets
1.5%
Return on equity
7.1%
Return on invested capital
6.4%
Return on capital employed
5.6%
Return on sales
12.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-0.59%
1 week
-7.74%
1 month
0%
1 year
-32.59%
YTD
5.62%
QTD
5.62%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.23B
Gross profit
$7.59B
Operating income
$1.96B
Net income
$726M
Gross margin
46.8%
Net margin
4.5%
TEVA's operating income has soared by 166% from the previous quarter and by 150% YoY
The operating margin has soared by 166% QoQ and by 152% YoY
TEVA's net income has surged by 119% since the previous quarter and by 118% year-on-year
The net margin has surged by 119% since the previous quarter and by 119% year-on-year

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
12.82
P/B
0.89
P/S
0.57
EV/EBIT
15.61
EV/EBITDA
9.2
EV/Sales
1.94
Teva Pharmaceutical Industries's EPS has surged by 118% QoQ and by 118% YoY
TEVA's price to book (P/B) is 18% lower than its last 4 quarters average of 1.1 and 10% lower than its 5-year quarterly average of 1.0
Teva Pharmaceutical Industries's equity has increased by 9% YoY
The P/S is 28% below the 5-year quarterly average of 0.8 and 17% below the last 4 quarters average of 0.7
TEVA's revenue is down by 2.6% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
The company's return on invested capital has surged by 173% QoQ and by 159% YoY
Teva Pharmaceutical Industries's return on sales has surged by 172% QoQ and by 158% YoY
TEVA's ROE has soared by 122% YoY and by 118% from the previous quarter
Teva Pharmaceutical Industries's return on assets has surged by 120% YoY and by 119% QoQ

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 31% greater than the total liabilities
The total liabilities fell by 7% YoY and by 3.9% QoQ
TEVA's quick ratio is down by 5% from the previous quarter
The debt is 131% greater than the equity
TEVA's debt to equity is down by 15% YoY and by 7% from the previous quarter
Teva Pharmaceutical Industries's equity has increased by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.